Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ProQR ( (PRQR) ) just unveiled an update.
ProQR Therapeutics N.V. announced its financial results for the third quarter and the nine-month period ending September 30, 2025. The company reported a decrease in revenue compared to the previous year, with €2,882,000 for the quarter and €11,218,000 for the nine-month period. Operating costs increased, leading to a higher operating loss of €11,284,000 for the quarter and €34,349,000 for the nine months. The results reflect ongoing challenges in the biotechnology sector, impacting ProQR’s financial performance and highlighting the need for strategic adjustments to improve profitability.
The most recent analyst rating on (PRQR) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.
Spark’s Take on PRQR Stock
According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.
ProQR’s overall stock score is primarily impacted by its significant financial challenges, including declining revenue and persistent losses. Technical analysis provides some positive signals with the stock trading above key moving averages, but valuation remains a concern with a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on PRQR stock, click here.
More about ProQR
ProQR Therapeutics N.V. operates in the biotechnology industry, focusing on the development of RNA therapies for genetic eye diseases. The company is based in the Netherlands and is dedicated to creating innovative solutions for patients with unmet medical needs in the ophthalmology sector.
Average Trading Volume: 464,779
Technical Sentiment Signal: Buy
Current Market Cap: $250.4M
For a thorough assessment of PRQR stock, go to TipRanks’ Stock Analysis page.